Business
Idorsia to present at J.P. Morgan 2026 Healthcare Conference
Allschwil, Switzerland – January 12, 2026Idorsia Ltd (SIX: IDIA) announces that Srishti Gupta, MD, Chief Executive Officer of Idorsia, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 10:30 am PST / 7:30 pm CET. The conference will take place at the Westin St. Francis hotel in San Francisco, USA. Dr Gupta will share how, with two products entering value-acceleration phase and an innovative pipeline poised to deliver the next generations of brea
About this update from Idorsia Ltd.
[{"type":"image","alt":"Idorsia Pharmaceuticals Ltd","displaySize":"","headline":null,"caption":"Idorsia Pharmaceuticals Ltd","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":138,"url":"https://media.zenfs.com/en/globenewswire.com/78a4ac48860a5805262d0e653fb52e9a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/atcBYtwjtI326vFfueDYtQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/78a4ac48860a5805262d0e653fb52e9a","width":300,"height":138}},"lazy":false},{"type":"text","content":"Allschwil, Switzerland – January 12, 2026Idorsia Ltd (SIX: IDIA) announces that Srishti Gupta, MD, Chief Executive Officer of Idorsia, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 10:30 am PST / 7:30 pm CET. The conference will take place at the Westin St. Francis hotel in San Francisco, USA.","length":350,"tagName":"p"},{"type":"text","content":"Dr Gupta will share how, with two products entering value-acceleration phase and an innovative pipeline poised to deliver the next generations of breakthrough medicines, Idorsia is on a path to profitability and growth.","length":219,"tagName":"p"},{"type":"text","content":"Follow this link to access the live audio stream. A replay will be available on the company website after the event under Investors / News & Events.","length":152,"tagName":"p"},{"type":"text","content":"Srishti Gupta, MD, Chief Executive Officer of Idorsia, commented: “Idorsia represents a rare combination: A commercial-stage pharma company with two products that have blockbuster potential and a highly innovative pipeline of first- or best-in-class medicines. We have a clear path to making QUVIVIQ the standard of care in insomnia – unlocking its value, and we are actively engaging in discussions to maximize the value of TRYVIO/JERAYGO and change the treatment landscape of uncontrolled hypertension with the only medication targeting the endothelin system. We also have plans to advance our pipeline, leading where we can and partnering where we should. In 2026, Idorsia will continue to build toward sustainable profitability and long-term growth, creating meaningful value for patients and shareholders alike.”","length":817,"tagName":"p"},{"type":"text","content":"The presentation will cover the highlights of the strong operat...